| Q45358050 | (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation |
| Q40067112 | 18F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation. |
| Q37855078 | A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients |
| Q42213685 | A comparative study of the use of selective digestive decontamination prophylaxis in living-donor liver transplant recipients. |
| Q38938297 | A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients |
| Q54290180 | A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. |
| Q40079187 | A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells |
| Q57056061 | Accuracy of diagnostic tests and a new algorithm for diagnosing cytomegalovirus colitis in inflammatory bowel diseases: a diagnostic study |
| Q40425776 | Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients. |
| Q47397747 | An Early Immediate Early Protein IE-1-Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation |
| Q42951982 | An Integrative Approach for the Transplantation of High-Risk Sensitized Patients |
| Q42270252 | Analysis of plasma surfactant protein D levels in lung transplant recipients |
| Q94326479 | Anti‐herpesvirus prophylaxis versus placebo, no treatment or pre‐emptive treatment in hemato‐oncological malignancies |
| Q40698934 | Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples |
| Q44495078 | Aspergillus infection in lung transplant patients: incidence and prognosis |
| Q54566425 | Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance. |
| Q42284503 | Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study |
| Q40703339 | Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder. |
| Q48334482 | Association between baseline serum hepcidin levels and infection in kidney transplant recipients: Potential role for iron overload |
| Q41427501 | Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients. |
| Q37408216 | Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation |
| Q38733949 | Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting |
| Q37199764 | Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum |
| Q37318303 | Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients |
| Q45070975 | Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients. |
| Q58854026 | Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study |
| Q82566053 | Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients |
| Q40101877 | Clinical and microbiological epidemiology of early and late infectious complications among solid-organ transplant recipients requiring hospitalization. |
| Q54289718 | Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. |
| Q39437974 | Clinical significance of the single nucleotide polymorphism TLR2 R753Q in heart transplant recipients at risk for cytomegalovirus disease |
| Q37867765 | Common infections in the lung transplant recipient |
| Q36288594 | Correlation and clinical utility of pp65 antigenemia and quantitative polymerase chain reaction assays for detection of cytomegalovirus in pediatric renal transplant patients |
| Q57515316 | Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience |
| Q92882471 | Current Knowledge about the Effect of Nutritional Status, Supplemented Nutrition Diet, and Gut Microbiota on Hepatic Ischemia-Reperfusion and Regeneration in Liver Surgery |
| Q37836967 | Current approaches to the management of highly sensitized kidney transplant patients |
| Q33416126 | Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. |
| Q42878334 | Cytomegalovirus appendicitis with concurrent bacteremia after chemotherapy for acute leukemia |
| Q40355862 | Cytomegalovirus colitis in patients without inflammatory bowel disease: a single center study |
| Q42283057 | Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. |
| Q37407845 | Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation |
| Q42216126 | Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients |
| Q39233808 | Cytomegalovirus infection associated with inflammatory bowel disease |
| Q47239011 | Cytomegalovirus infection in living-donor and cadaveric lung transplantations |
| Q26801802 | Cytomegalovirus infection in transplant recipients |
| Q42260511 | Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients |
| Q37359332 | Cytomegalovirus infections in solid organ transplantation: a review |
| Q41342348 | Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice |
| Q42281180 | Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience. |
| Q37825594 | Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation |
| Q40721769 | Detection of Epstein-Barr virus DNAemia after lung transplantation and its potential relationship with the development of post-transplant complications |
| Q37272283 | Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients |
| Q64238463 | Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: A PRISMA-compliant article |
| Q38186156 | Diagnostic value of serum procalcitonin in solid organ transplant recipients: a systematic review and meta-analysis |
| Q37157642 | Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection |
| Q36752124 | Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity? |
| Q42852632 | Drug-resistant cytomegalovirus in transplant recipients: a French cohort study |
| Q35544428 | Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients |
| Q92405136 | Effect of Type of Dialysis on CMV-Specific CD8+ T Cells in Kidney Transplant Candidates |
| Q38802439 | Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients |
| Q34432814 | Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients. |
| Q37003621 | Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation. |
| Q37423352 | Elevated CXCL10 (IP-10) in bronchoalveolar lavage fluid is associated with acute cellular rejection after human lung transplantation |
| Q91740932 | Epidemiology, Risk Factors, and Outcomes of Opportunistic Infections after Kidney Allograft Transplantation in the Era of Modern Immunosuppression: A Monocentric Cohort Study |
| Q27024229 | Epstein-Barr virus infection and posttransplant lymphoproliferative disorder |
| Q45355371 | Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid |
| Q47560250 | Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients |
| Q95424070 | Excessive immunosuppression in kidney transplant patients: prevalence and outcomes |
| Q27026499 | Flow cytometry and solid organ transplantation: a perfect match |
| Q36747670 | Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases |
| Q35167034 | Heteromerization of human cytomegalovirus encoded chemokine receptors |
| Q37308147 | High-quality CMV-specific CD4+ memory is enriched in the lung allograft and is associated with mucosal viral control |
| Q35694674 | Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation |
| Q43536491 | Human cytomegalovirus infection in lung transplant recipients triggers a CXCL-10 response. |
| Q43222023 | Immune cell functional assay in monitoring of adult liver transplantation recipients with infection |
| Q40448570 | Immune function monitoring in lung transplantation using adenosine triphosphate production: time trends and relationship to postoperative infection. |
| Q36831205 | Immune surveillance and lymphoid malignancy in immunocompromised host |
| Q37050965 | Immunobiology of human cytomegalovirus: from bench to bedside. |
| Q45360184 | Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients |
| Q40267366 | Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation. |
| Q42252471 | Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients |
| Q42206788 | Impact of infectious disease consultation on the clinical and economic outcomes of solid organ transplant recipients admitted for infectious complications |
| Q44407642 | Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial |
| Q52676520 | Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol. |
| Q40102118 | Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. |
| Q41496012 | Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis |
| Q35834958 | Infections after lung transplantation: time of occurrence, sites, and microbiologic etiologies |
| Q38006193 | Infections caused by herpes viruses other than cytomegalovirus in solid organ transplant recipients. |
| Q36526167 | Infections in pediatric solid organ transplant recipients |
| Q40912977 | Infectious Complications Following Small Bowel Transplantation |
| Q61808800 | Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation |
| Q46463303 | Influence of cytomegalovirus disease in outcome of solid organ transplant patients. |
| Q45367418 | Intensive polyoma virus nephropathy treatment as a preferable approach for graft surveillance. |
| Q42272268 | Interactions between anti-infective agents and immunosuppressants in solid organ transplantation |
| Q47665118 | Into thin air: Predicting PTLD in pediatric lung transplant patients. |
| Q50483235 | Introduction: Infections in solid organ transplantation. |
| Q59359554 | Investigation of BK Virus by Real-Time Polymerase Chain Reaction in Patients With Allogeneic Bone Marrow Transplantation |
| Q37954420 | Is prevention the best treatment? CMV after lung transplantation |
| Q51579669 | Kidney transplantation for high-risk sensitized patients - the "Heidelberg algorithm". |
| Q42223053 | Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation |
| Q37192117 | Laboratory assays for Epstein-Barr virus-related disease |
| Q92490883 | Late Cytomegalovirus Infection in Kidney Transplant Recipients after a Six-Month Prevention Protocol |
| Q38010486 | Lung transplant infection |
| Q37824825 | Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options |
| Q41918077 | Mechanisms of human cytomegalovirus infection with a focus on epidermal growth factor receptor interactions |
| Q42113870 | Modeling rejection immunity. |
| Q37848137 | Monitoring and managing viral infections in pediatric renal transplant recipients |
| Q92338104 | Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series |
| Q40630330 | Monitoring of intracellular adenosine triphosphate in CD4(+) T cells to predict the occurrence of cytomegalovirus disease in kidney transplant recipients |
| Q64260637 | Non-immunological complications following kidney transplantation |
| Q59230712 | Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody |
| Q57493311 | Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome? |
| Q58740384 | Optimal immunosuppressor induces stable gut microbiota after liver transplantation |
| Q57750563 | Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients |
| Q52656859 | Outcome of renal transplantation in small infants: a match-controlled analysis. |
| Q41368785 | Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid |
| Q36017708 | Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status |
| Q38908687 | Peripheral Blood Epstein-Barr Viral Nucleic Acid Surveillance as a Marker for Posttransplant Cancer Risk |
| Q37975458 | Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. |
| Q38112050 | Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies |
| Q40255111 | Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study. |
| Q35574186 | Post-transplant lymphoproliferative disorder: case report and review of susceptibility to EBV in the Scottish adult renal transplant pool |
| Q40645930 | Post-transplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients |
| Q36194638 | Posttransplant Lymphoproliferative Disorder of the Thorax: CT and FDG-PET Features in a Single Tertiary Referral Center |
| Q38680172 | Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management |
| Q37892707 | Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review |
| Q46001931 | Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience. |
| Q53120860 | Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction. |
| Q36293963 | Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients |
| Q42216221 | Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort. |
| Q40389617 | Preventive Strategies Against Cytomegalovirus and Incidence of α-Herpesvirus Infections in Solid Organ Transplant Recipients: A Nationwide Cohort Study. |
| Q47378342 | Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. |
| Q40956620 | Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy. |
| Q44100013 | Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients |
| Q54211464 | Prospective Assessment of Adenovirus Infection in Pediatric Kidney Transplant Recipients. |
| Q43909393 | Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. |
| Q33671565 | Prospective, comprehensive, and effective viral monitoring in Cuban children undergoing solid organ transplantation |
| Q89907695 | Protective Effects of Cytomegalovirus DNA Copies ≧1000/mL for AML Patients in Complete Remission After Single Cord Blood Transplantation |
| Q58074723 | QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity |
| Q36952467 | Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial. |
| Q35051236 | Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. |
| Q33740315 | Reactivation of multiple viruses in patients with sepsis |
| Q64080560 | Readiness for Firefighting: A Heart Transplant Patient's Quest to Return to Work |
| Q57568519 | Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case-Control Study |
| Q40262029 | Risk Factors and Outcomes of Ganciclovir Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients |
| Q90705079 | Risk Factors for the Development of Cytomegalovirus Resistance in Solid Organ Transplantation: A Retrospective Case-Control Study |
| Q57569032 | Risk Factors, Clinical Features, and Outcomes of Toxoplasmosis in Solid-Organ Transplant Recipients: A Matched Case-Control Study |
| Q35140692 | Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis |
| Q28298477 | Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study |
| Q40745065 | Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients. |
| Q40358580 | Serum sCD30: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation |
| Q37840478 | Simkania negevensis and acute cellular rejection in lung transplant recipients. |
| Q34455315 | Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation |
| Q79899475 | Surgical site infections in liver recipients in the early posttransplantation period: etiological agents and susceptibility profiles |
| Q51802922 | Surgical site infections in the early posttransplant period after simultaneous pancreas-kidney transplantation. |
| Q36099296 | Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response |
| Q41090910 | T-lymphocyte subsets in lung transplant recipients: association between nadir CD4 T-cell count and viral infections after transplantation |
| Q37821326 | The BK virus in renal transplant recipients-review of pathogenesis, diagnosis, and treatment |
| Q38852662 | The Emerging Role of Nanotechnology in Cell and Organ Transplantation |
| Q62588845 | The Status of BK Polyomavirus Replication in Adult Renal Transplant Recipients in Northeastern Poland |
| Q40173113 | The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients |
| Q50569364 | The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation. |
| Q38367389 | The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: A systematic review |
| Q37304893 | The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation |
| Q44876294 | Tuberculosis in solid-organ transplant recipients: disease characteristics and outcomes in the current era. |
| Q37796146 | Two donor-related infections in a heart transplant recipient: One common, the other a tropical surprise |
| Q41177320 | Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome |
| Q37837487 | Understanding human T-cell-mediated immunoregulation through herpesviruses |
| Q38293175 | Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis |
| Q37726624 | Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder |
| Q37949634 | Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation |
| Q33522300 | Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients |
| Q36071675 | Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections |
| Q40230220 | Very late relapse of PTLD 10 yr after allogeneic HSCT and nine yr after stopping immunosuppressive therapy |
| Q38240085 | Viral surveillance and subclinical viral infection in pediatric kidney transplantation. |
| Q34761349 | What's new in clinical solid organ transplantation by 2013. |
| Q79748079 | [Immunosuppression and infection in transplant recipients] |